Alivus Life Sciences Q2 FY27 Profit Jumps 51% to Rs 197 Crore; CDMO Revenue Up 80% as Solapur API Site Nears Start

Alivus Life Sciences (formerly Glenmark Life Sciences) posted Q2 FY27 revenue of Rs 682 crore, up 16%, and PAT of Rs 197 crore, up 51.3%. Non-Glenmark sales rose 20.8% to 79% of revenue, CDMO revenue grew about 80% to Rs 50 crore, and Solapur Phase 1 goes live in Q3 FY27.